Currently, there are 20.34M common shares owned by the public and among those 15.32M shares have been available to trade.
The company’s stock has a 5-day price change of -0.45% and -61.44% over the past three months. TRML shares are trading -40.60% year to date (YTD), with the 12-month market performance down to -36.27% lower. It has a 12-month low price of $9.18 and touched a high of $48.31 over the same period. TRML has an average intraday trading volume of 455.09K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 7.84%, -1.20%, and -36.60% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Tourmaline Bio Inc (NASDAQ: TRML) shares accounts for 72.05% of the company’s 20.34M shares outstanding.
It has a market capitalization of $398.86M and a beta (3y monthly) value of 2.37. The earnings-per-share (ttm) stands at -$6.50. Price movements for the stock have been influenced by the stock’s volatility, which stands at 9.00% over the week and 6.54% over the month.
Earnings per share for the fiscal year are expected to increase by 67.78%, and -9.27% over the next financial year.
Looking at the support for the TRML, a number of firms have released research notes about the stock. Jefferies stated their Buy rating for the stock in a research note on December 15, 2023, with the firm’s price target at $41. H.C. Wainwright coverage for the Tourmaline Bio Inc (TRML) stock in a research note released on December 04, 2023 offered a Buy rating with a price target of $48. Truist was of a view on November 17, 2023 that the stock is Buy, while Guggenheim gave the stock Buy rating on October 31, 2023, issuing a price target of $50. Piper Sandler on their part issued Overweight rating on October 25, 2023.
